The Trump administration is reviewing a contract extended to Moderna in the final days of the Biden administration.

Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.

Shares of vaccine maker Moderna dropped more than 5% late Wednesday after reports that the Health and Human Services ...

Moderna’s reliance on its COVID vaccine for revenue has become a vulnerability as sales decline and the company invests heavily in its product pipeline. The bird flu vaccine contract was expedited due ...

American pharmaceutical company Moderna (MRNA) is reportedly under scrutiny by U.S. President Donald Trump’s team, which is ...

Moderna Inc.'s stock tumbled 4% Thursday, after a report that health officials are reviewing a contract the company won from the Biden administration to support its efforts to develop a bird-flu ...

U.S. health officials are reevaluating a $590M bird flu vaccine contract that was awarded to Moderna ( NASDAQ: MRNA) by the ...

US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

Moderna shares fell 3% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine. Moderna was awarded the ...

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

Allspring Global Investments Holdings LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 12.2% in the fourth quarter, Holdings Channel reports. The firm owned 15,368 shares of ...